Quality of life among injectable and oral disease-modifying therapy users in the Pacific Northwest Multiple Sclerosis Registry

Quality of life among injectable and oral disease-modifying therapy users in the Pacific Northwest Multiple Sclerosis Registry

Abstract Background Nine oral disease-modifying therapies (DMTs) have been approved for the treatment of multiple sclerosis (MS) in the United States. Few studies have examined self-reported quality of life (QoL) and functional status outcomes among patients who switch to oral medications from injec...

Full description

Bibliographic Details
Main Authors: Tamela Stuchiner, Lindsay Lucas, Elizabeth Baraban, Kateri J. Spinelli, Chiayi Chen, Alden Smith, Lobat Hashemi, Stanley Cohan
Format: Article
Language:English
Published: BMC 2020-12-01
Series:BMC Neurology
Subjects:
Multiple sclerosis
Disease-modifying therapies
Oral DMT
Injectable DMT
Quality of life
Disability
Online Access:https://doi.org/10.1186/s12883-020-02016-4

Internet

https://doi.org/10.1186/s12883-020-02016-4

Similar Items